Texas (August 30, 2013) Wax Ink has issued a Negative Investment Interest opinion for AmSurg Corporation (Nasdaq: AMSG) based on a recent baseline equity review which placed fair value between $20-$27.
The recent close of $38.10 is approximately 214% above the fair value buy target for the stock and approximately 53% above the fair value close target for the stock. The recent close is also 3% above analysts' twelve-month $37.00 median price target for the stock.
The recent close represents a 28% increase in the year over year price of the stock, while for the same period sales increased 31%, earnings increased 15%, and debt decreased 37%.
The stock currently has a trailing twelve-month PE Ratio of 14, and a PEG Ratio of 1.0 basis estimated forward earnings growth of 13%.
In the past 52 weeks, share prices have moved between a high of $41.00 and a low of $25.00, placing equilibrium at $35.95.
Basis the recent close, the stock is trading 8% below the 52 week high, 34% above the 52 week low, and 6% above equilibrium.
The three-month average daily trading volume for the stock is approximately 104,000 shares.
AmSurg Corporation through its subsidiaries, engages in the acquisition, development, and operation of ambulatory surgery centers in partnership with physicians in the United States.
The company's listed competitors include HCA Holdings, Inc., Symbion, Inc.and United Surgical Partners International, Inc.
Financial information that may be contained herein, is based on the company's most recent annual SEC filing for year ending December 31, 2012.
All prices are per share unless otherwise noted.
Wax Ink currently has no investment position in any company mentioned in this alert.
For use by Accredited Investors as defined under Title 17, CFR §230.500, Regulation D.
Copyright © 2013 Wax Ink
Wax Ink is a baseline equity research company not licensed or registered with any government agency
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.